>> to me the SMA program is what I find most interesting <<
Wo! Phase I about to launch, blinded and placebo controlled....
clinicaltrials.gov
(pointer from Doug Heuring)
I would have guessed 2016. Means that preclinical has long been running, well before recently published results. Nice.
Our checks suggest this drug, code-named RO6885247 on the site, is Roche/PTC’s compound, RG7800. RG7800’s transition into patient trials appears to have occurred sooner than originally anticipated, supporting Roche’s commitment to the program. Our base case views this 20-week Phase I trial as a prelude to a potentially pivotal Phase II trial in the most severely affected (Type I) SMA patients. However, we note that remarkable results, with clear OS benefit, are possible even in subsets of this 48-patient trial and would, in our opinion, be suitable for registration given unmet need in this patient group.
smarteranalyst.com
aside.... As you probably know, the twitter biotech gang, most often correct, loves to bash ptct. |
